UNIVERSAL BIOSENSORS INC Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in AUD from Q4 2016 to Q2 2024

Taxonomy & unit
us-gaap: AUD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Universal Biosensors Inc quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and growth rate from Q4 2016 to Q2 2024.
  • Universal Biosensors Inc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending June 30, 2024 was AUD17M, a 2.33% increase year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (AUD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 17M +387K +2.33% Jun 30, 2024 10-Q 2024-08-02
Q1 2024 7.39M -13.9M -65.2% Mar 31, 2024 10-Q 2024-05-02
Q4 2023 10.6M -16.2M -60.5% Dec 31, 2023 10-Q 2024-08-02
Q3 2023 16.6M -11.7M -41.3% Sep 30, 2023 10-Q 2023-10-30
Q2 2023 16.6M -16.8M -50.2% Jun 30, 2023 10-Q 2023-07-31
Q1 2023 21.3M +8.26M +63.5% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 26.8M +8.73M +48.2% Dec 31, 2022 10-K 2024-02-29
Q3 2022 28.4M +9.65M +51.6% Sep 30, 2022 10-Q 2022-10-27
Q2 2022 33.4M +10.9M +48.5% Jun 30, 2022 10-Q 2022-08-10
Q1 2022 13M -11.8M -47.5% Mar 31, 2022 10-Q 2022-04-29
Q4 2021 18.1M -9.96M -35.5% Dec 31, 2021 10-K 2023-02-24
Q3 2021 18.7M -9.7M -34.1% Sep 30, 2021 10-Q 2021-10-29
Q2 2021 22.5M -9.64M -30% Jun 30, 2021 10-Q 2021-08-06
Q1 2021 24.8M -10.1M -28.9% Mar 31, 2021 10-Q 2021-04-30
Q4 2020 28.1M -9.14M -24.6% Dec 31, 2020 10-K 2022-02-24
Q3 2020 28.4M -6.43M -18.5% Sep 30, 2020 10-Q 2020-10-29
Q2 2020 32.1M -18.7M -36.8% Jun 30, 2020 10-Q 2020-07-24
Q1 2020 34.9M -17.4M -33.3% Mar 31, 2020 10-Q 2020-04-24
Q4 2019 37.2M +25.1M +207% Dec 31, 2019 10-K 2021-02-24
Q3 2019 34.8M +3.06M +9.62% Sep 30, 2019 10-Q 2020-10-29
Q2 2019 50.9M +19.8M +63.4% Jun 30, 2019 10-Q 2020-07-24
Q1 2019 52.2M +23.7M +83.2% Mar 31, 2019 10-Q 2020-04-24
Q4 2018 12.1M -17.4M -58.9% Dec 31, 2018 10-Q 2020-10-29
Q3 2018 31.8M +8.7M +37.7% Sep 30, 2018 10-Q 2019-11-04
Q2 2018 31.1M +7.94M +34.3% Jun 30, 2018 10-Q 2019-07-25
Q1 2018 28.5M +7.5M +35.7% Mar 31, 2018 10-Q 2019-04-30
Q4 2017 29.5M +5.87M +24.9% Dec 31, 2017 10-K 2020-02-26
Q3 2017 23.1M Sep 30, 2017 10-Q 2018-10-30
Q2 2017 23.2M Jun 30, 2017 10-Q 2018-08-13
Q1 2017 21M Mar 31, 2017 10-Q 2018-04-27
Q4 2016 23.6M Dec 31, 2016 10-K 2019-02-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.